Amgen Inc. (AMGN), headquartered in Thousand Oaks, California, discovers, develops, manufactures, and delivers human therapeutics. With a market cap of $174.4 billion, the company focuses on human therapeutics and concentrates on innovating novel medicines based on cellular and molecular biology. The drug manufacturing giant is expected to announce its fiscal third-quarter earnings for 2024 before the market opens on Wednesday, Oct. 30. Ahead of the event, analysts expect AMGN to report a profit of $5.10 per share on a diluted basis, up 2.8% from $4.96 per share in the year-ago quarter. The co…